biostudies-literatureBorthwick NInternational Aids Vaccine InitiativeEuropean & Developing Countries Clinical Trials Partnership (EDCTP)Medical Research CouncilNIHR Oxford Biomedical Research CentreForeign, Commonwealth and Development OfficeInternational AIDS SocietyNational Institute for Health Research (NIHR)United States Agency for International DevelopmentHorizon 2020European Commission100956https://www.ebi.ac.uk/biostudies/studies/S-EPMC7618664biostudies-literatureUnknown6(3)<h4>Background</h4>An HIV-1 vaccine is long overdue. Although vaccine research focuses on the induction of broadly neutralising antibodies, challenging infections such as HIV-1 could require parallel induction of protective T cells. It is important to recognise that not all T cells contribute to protection equally. Previously, we developed a T-cell immunogen-based bivalent mosaic vaccine, HIVconsvX, delivered by vaccine vectors ChAdOx1 and modified vaccinia Ankara. In this study, we tested the HIVconsvX vaccine regimen for the first time in humans. Other ongoing trials will assess the contribution of the vaccine-induced killer T cells to the control of HIV-1.<h4>Methods</h4>HIV-CORE 005.2 was an open-label, dose-escalation, first-in-human, phase 1 trial done at the Centre for Clinical VaccThe Lancet. MicrobeSafety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK.PMC7618664681137-EAVI2020MR/N023668/1NIHR203311SRIA2015-1066Fernandez NGlaze MHayes PJHanke TPoulton IAkis Yildirim BMBaines ACrook AQuaddy JWatson MByard NPlatt AConway OLuciw MBaker MLarkworthy CThomas MJenkin DWee EGCicconi PBorthwick NfalseSafety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK.<h4>Background</h4>An HIV-1 vaccine is long overdue. Although vaccine research focuses on the induction of broadly neutralising antibodies, challenging infections such as HIV-1 could require parallel induction of protective T cells. It is important to recognise that not all T cells contribute to protection equally. Previously, we developed a T-cell immunogen-based bivalent mosaic vaccine, HIVconsvX, delivered by vaccine vectors ChAdOx1 and modified vaccinia Ankara. In this study, we tested the HIVconsvX vaccine regimen for the first time in humans. Other ongoing trials will assess the contribution of the vaccine-induced killer T cells to the control of HIV-1.<h4>Methods</h4>HIV-CORE 005.2 was an open-label, dose-escalation, first-in-human, phase 1 trial done at the Centre for Clinical Vacc2025-01-01T00:00:00Z2025 Mar2026-06-13T05:04:32.426Z2026-06-13T03:09:05.343ZS-EPMC76186643961292110.1016/j.lanmic.2024.100956